Background {#Sec1}
==========

Nasopharyngeal carcinoma (NPC) is the malignant cancer occurring on the top and lateral wall of nasopharynx cavity \[[@CR1]\], which is prevalent in southeast Asia especially in southern China. Most of the NPC patients are diagnosed at the stage of III or IV, and the 5 years survival rate is 50%--60% \[[@CR2]\]. It has been proved that Epstein-Barr virus infection, genetic susceptibility, environmental factors, dysfunction of oncogenes or suppressor genes and life styles are all associated with NPC tumorigenesis \[[@CR3]\]. The process of nasopharyngeal carcinoma from mucosal epithelium of the nasopharynx, to low-grade dysplastic epithelium, high-grade dysplastic epithelium, invasive and metastasis cancer involves in multiple genes alteration, for example, alleles loss on 3p, 9p, 11q, 13q, 14q, 16q and gained on chromosomes 8,12 \[[@CR4], [@CR5]\]. p53R2 located on chromosome 8q23.1 is a target of p53 gene. When DNA is damaged, the cell cycle is blocked at G1 and G2 stage. Subsequently, p53R2 is upregulated and accumulated in the nuclear to provide dNTP to repair the damaged DNA \[[@CR6], [@CR7]\]. Different phenotypes of p53R2 have been found in various human cancers. In small cell lung cancer and esophageal cancer, high level of p53R2 expression has been shown to be a biomarker of tumor invasion and worse prognosis, which indicates p53R2 may be an oncogenic role in these cancers \[[@CR8], [@CR9]\]. While in colorectal cancer, overexpression of p53R2 indicates a good outcome for the patients, suggesting that p53R2 may be a tumor suppressor \[[@CR10], [@CR11]\]. However, it's still unclear what's the expression status of p53R2 expression in NPC and its clinicopathological significance. Here we used IHC to evaluate the protein level of p53R2 in nasopharyngeal carcinoma tissues and apply the statistic analysis methods to identify the association between p53R2 and the prognostic significance of nasopharyngeal carcinoma.

Methods {#Sec2}
=======

Patients and specimens {#Sec3}
----------------------

In this study, 201 specimens of NPC in Sun Yat-sen University Cancer Center from January 2001 to October 2012 were collected. The cases selected were based on the following criteria: pathologically confirmed as nasopharyngeal cancer with available biopsy specimens for immunohistochemistry; no previous malignant disease or a second primary tumor; without radiotherapy, chemotherapy and surgery treatment history; completed follow-up data. Patients who had no complete clinical follow-up data or had died from other unknown reasons were excluded. The pTMN stage was defined based on the sixth edition TNM classification criteria established by the International Union Against Cancer (UICC, 2002). All the experiments done in this study were approved by the institute research medical ethics committee of Sun Yat-sen University.

Immunohistochemistry (IHC) {#Sec4}
--------------------------

IHC was performed using standard EnVision method. The paraffin-embedded tissue blocks were cut into 3 μm thick sequential sections, the slides were dried and deparaffinized in xylene, rehydrated through graded alcohol, immersed in 3% hydrogen peroxide for 10 min to block endogenous peroxidase activity and antigen retrieved by pressure cooking for 3 min in citrate buffer (pH = 6). Then the slides were incubated with 5% BSA for 15 min to reduce nonspecific reaction. Subsequently, the slides were incubated with the rabbit monoclonal antibody anti-p53R2 (Abcam, ab154194, 1:400 dilution) for 50 min at 37 °C. The slides were sequentially incubated with a secondary antibody (Envision, Dako, Denmark) for 30 min in the incubator at 37 °C, and stained with DAB (3,3-diaminobenzidine). Finally, the sections were counterstained with Mayer's hematoxylin, dehydrated and mounted. A negative control was obtained by replacing the primary antibody with a normal rabbit IgG.

IHC evaluation {#Sec5}
--------------

p53R2 staining was mainly observed at the cytoplasm, and the positively stained cells were brown or yellow. Immune reactivity was scored by evaluating the number of positive cells and the positive intensity score: (i) The percentage of positive tumor cells: take 5 fields every slide to counter the percentage in 5% increments from 0 to 100% (0 indicates negative staining). (ii) Positive intensity score: negative (0), weak (1), moderate (2) and strong (3). (iii) The scores obtained from intensity and the proportion (0--300 scores). We used the ROC curve to determine the cut-off value of p53R2 expression level in NPC. Two pathologists who were blind to the information of patients performed the scoring. If the results were different, then a third pathologist would participate to confirm the score.

Statistical analysis {#Sec6}
--------------------

SPSS software (version 21.0, SPSS, Chicago, IL) was used to operate the analysis. ROC analysis was performed to determine the cut-off value for p53R2 expression. We applied χ^2^ test to evaluate the relationship between p53R2 and NPC patients' clinicopathological characteristics. Univariate analysis was performed by the Kaplan-Meier. Cox regression analysis was employed to identify the independent prognostic factor. Two--tailed *P* value less than 0.05 was considered statistically significant.

Results {#Sec7}
=======

p53R2 expression in NPC tissues examined by IHC {#Sec8}
-----------------------------------------------

The positive expression of p53R2 by IHC analysis in nasopharyngeal carcinoma was primarily a cytoplasm pattern (Fig. [1](#Fig1){ref-type="fig"}) and the positive expression rate was 92.5% (186/201).Fig. 1Expression of p53R2 protein in NPC tissues. **a**, Negative expression; **b**, Low expression; **c**, Moderate expression; **d**, Strong expression

Cut-off value for p53R2 expression {#Sec9}
----------------------------------

ROC curve was used to identify the cut-off for p53R2. The point with both maximum sensitivity and specificity was chosen as the cut-off point \[[@CR12]\]. Area under the curve (AUC) and *P* value were shown in Table [1](#Tab1){ref-type="table"}. The sensitivity and specificity for each clinicopathological feature were plotted (Fig. [2](#Fig2){ref-type="fig"}). Therefore, we used the survival status as a state variable. The ROC curve analysis revealed that the cut-off value of the expression of p53R2 protein was 150 (*P* \< 0.05).Table 1AUC operating characteristic curve for each clinicopathological featureFeatureAUC (95% CI)*P* value^a^T stage0.557 (0.468--0.645)0.197N stage0.591 (0.469--0.712)0.124Survival status0.604 (0.509--0.698)0.047Clinical stage0.515 (0.405--0.624)0.776^a^Chi-square tests Fig. 2ROC curve analysis was employed to determine the cut-off value for high p53R2 expression in NPC. The sensitivity and specificity for each outcome were plotted: pN status (**a**), survival outcome (**b**), pT status (**c**), clinical stage (**d**)

Association of p53R2 expression with NPC patients' clinicopathological features {#Sec10}
-------------------------------------------------------------------------------

Further analysis showed that expression of p53R2 was significantly correlated with T stage (Table [2](#Tab2){ref-type="table"}, *P* = 0.043) and there was no significant association between p53R2 expression and other clinicopathological features, such as patient sex, age, lymph node metastasis, clinical stage, therapeutic regimen, relapse (Table [2](#Tab2){ref-type="table"}, *P* \> 0.05). As shown in this table, high-level of p53R2 was observed in 48.4% of stage T1 + T2 patients and in 33.6% of stage T3 + T4 patients.Table 2Correlation between the p53R2 expression and clinicopathological variables in NPC patientsVariableExpression of p53R2All casesLowHigh*P* valueGender0.217 Female5739 (68.4%)18 (31.6%) Male14485 (59.0%)59 (41.0%)Age0.593 ≤45.89^a^10466 (63.5%)38 (36.5%) \>45.899758 (59.8%)39 (40.2%)Clinical stage0.450 I-II3922(56.4%)17 (43.6%) III-IV162102(63.0%)60 (37.0%)T stage0.043 T1 + T26433 (51.6%)31 (48.4%) T3 + T413791 (66.4%)46 (33.6%)N stage0.469 N02819 (67.9%)9 (32.1%) N1 + N2 + N3173105 (60.7%)68 (39.3%)Therapy^b^0.205 Regimen 15034 (68.0%)16 (32.0%) Regimen 27246 (63.9%)26 (36.1%) Regimen 33114 (45.2%)17 (54.8%) Regimen 44830 (62.5%)18 (37.5%)Relapse0.543 Yes3020 (66.7%)10 (33.3%) No171104 (60.8%)67 (39.2%)^a^mean age; ^b^Regimen 1, radiation therapy;Regimen 2, chemoradiotherapy; Regimen 3, induction + radiation therapy; Regimen 4, induction + chemoradiotherapy

The relationship between p53R2 expression status and clinicopathological characteristics and NPC patients' survival {#Sec11}
-------------------------------------------------------------------------------------------------------------------

In this present study, the survival analysis showed that patients with high p53R2 expression had a better survival (*P* = 0.012, Fig. [3a](#Fig3){ref-type="fig"}). To explore the prognostic factor for NPC, we calculated the influence of the clinicopathological features on the prognosis of NPC, the mean survival period of patients with clinical stage I-II (mean: 149.60 months) was longer than that with clinical stage III-IV (mean: 126.65 months) (*P* = 0.021, Fig. [3b](#Fig3){ref-type="fig"}). The mean overall survival period for patients with older age was shorter than that with younger age; the difference was statistically different (*P* = 0.010, Fig. [3c](#Fig3){ref-type="fig"}). There was also a better survival for patients with stage T1 and T2 compared to patients with T3 and T4 (*P* = 0.038, Fig. [3d](#Fig3){ref-type="fig"}). We also observed a significantly different survival rate between the patients with N0 and the patients with N1--3 (*P* = 0.048, Fig. [3e](#Fig3){ref-type="fig"}). Recurrence was also found to be a significant prognostic factor for NPC (*P* \< 0.001, Fig. [3f](#Fig3){ref-type="fig"}). All the detailed data were shown in Table [3](#Tab3){ref-type="table"}.Fig. 3Different prognostic factors for survival outcome in 201 patients with NPC. The overall for each outcome were plotted: p53R2 expression (**a**), clinical stage (**b**), age (**c**), pT status (**d**), pN status (**e**), relapse (**f**) Table 3Univariate survival analysis of different prognostic factors in 201 patients with NPCVariableAll casesMean survival (months)Chi-square value*P*-valueGender2.2910.130 Male144125.36 Female57142.17Age6.6440.010 ≤45.89104141.09 \>45.8997118.95Clinical stage5.3100.021 I-II39149.60 III-IV162126.65T stage4.3230.038 T1 + T264142.54 T3 + T4137123.32N stage3.9150.048 N028146.06 N1 + N2 + N3173129.18Therap**y**2.8410.417 Regimen 150122.82 Regimen 272133.64 Regimen 331127.82 Regimen 448122.49Relapse32.950.000 No171138.15 Yes3091.75Expression Low124121.636.3470.012 High77143.32

To investigate the impact of the p53R2 protein expression on the survival of NPC patients with different subgroups, further analysis was performed regarding p53R2 expression in subsets of NPC patients in different clinical stage, pT stage, pN stage. We observed that the expression of p53R2 was a prognostic factor for stage III + IV (*P* = 0.015), pT3 + T4 (*P* = 0.025), pN1 + N2 + N3 (*P* = 0.012, Fig. [4](#Fig4){ref-type="fig"}).Fig. 4Kaplan-Meier survival analysis of p53R2 expression in subsets of NPC patients with different clinical stage and pT/pN stage. Clinical stage I + II (**a**), Clinical stage III + IV (**b**), pT1 + T2 (**c**), pT3 + T4 (**d**), pN0 (**e**), pN1 + N2 + N3 (**f**)

Independent prognostic factors for NPC patients {#Sec12}
-----------------------------------------------

The factors that had a significant difference in univariate analysis were further tested in the cox regression analysis, and the results suggested that p53R2 was an independent prognostic factor. Additionally, age and tumor relapse were independent prognostic factors for NPC patients as well (Table [4](#Tab4){ref-type="table"}).Table 4Cox multivariate analysis of prognostic factors on overall survivalVariableHazards ratio95% CI\**P* valueAge (\>45.89 vs. ≤45.89)3.141.58--6.250.001Clinical stage (III-IV vs. I-II)3.271.00--10.670.050Relapse (Yes vs. No)5.973.10--11.490.000p53R2 expression (High vs. Low)0.390.18--0.850.018\*CI, confidence interval;

The relationship between the expression of p53R2 and the overall survival rate {#Sec13}
------------------------------------------------------------------------------

We utilized Kaplan-Meier analysis to evaluate the relationship between the expression of p53R2 and the survival rate of NPC patients (Table [3](#Tab3){ref-type="table"}). In the high p53R2 expression group: this subgroup had a mean survival time of 143.32 months; the 5-year survival rate was 96.00%, and the 10-year survival rate was 82.90%. However, in low p53R2 expression group: the mean survival period was 121.63 months, the 5-year survival rate was 83.20%, and the 10-year survival rate was 63.20% (Table [5](#Tab5){ref-type="table"}).Table 5The expression of p53R2 for five-year survival rate and ten-year survival ratep53R2 expressionMean survival time (months)Five - year survival rate (%)Ten - year survival rate (%)Low121.6383.2063.20High143.3296.0082.90

Discussion {#Sec14}
==========

p53R2, a ribonucleotide reductase small subunit, belongs to the ribonucleotide reductase family. p53R2 offers dNTPs for DNA replication and repair \[[@CR13]\]. p53R2 is essential for DNA repair, mitochondrial DNA synthesis, protection against oxidative stress, chromosomal instability, chronic inflammation and tumorigenesis \[[@CR7], [@CR14], [@CR15]\]. Recent study has found that p53R2 point mutation in HCT116 (a colorectal cancer cell line) could lead to ribonucleotide reductase (RR) activity attenuation and dysfunction of DNA repair \[[@CR16]\]. Another study also indicated that in nontransformed cells, p53R2 was critical for maintaining mtDNA and repairing UV damaged DNA during quiescence \[[@CR17]\].

Herein, we estimated the protein status of p53R2 in 201 NPC specimens by IHC. The result demonstrated that p53R2 was positive in 92.5% of the NPC, and further analysis revealed a significant correlation between p53R2 expression and pT stage by chi-square test. Univariate Kaplan-Meier analysis indicated that the status of p53R2 expression have a significant impact on patient survival. Cox multivariate analysis found that p53R2 was an independent prognostic factor for NPC. Taken together, our results suggest that p53R2 expression is a reliable biomarker for prognosis of NPC.

There are a few reports about the relationship between p53R2 expression and the prognosis of human cancers. In a study on colorectal cancer, high-level of p53R2 expression indicated patients having a longer survival period and could be a favorable prognostic factor \[[@CR10], [@CR11]\]. In consistent with this study, our data show that p53R2 expression is negatively correlated with clinicopathological parameters and predicts a good outcome of NPC patients. Several previous studies reported that the positive staining of p53R2 examined by IHC, was observed dominantly in the cytoplasm of tumor cells, such as colon cancer, lung cancer and esophageal cancer \[[@CR9], [@CR18], [@CR19]\]. In response to DNA damage stress, p53R2 will translocate from cytoplasm to nucleus \[[@CR20]\]. M2B may translocate from the cytoplasm into the nucleus and allow dNTPs to initiate DNA synthesis in KB cells under physiological conditions \[[@CR21]\].

More and more researchers show that p53R2 plays a key role in many biological processes and diseases including tumors. In the field of mitochondrial DNA disorder, RRM2B (encoding p53R2) is critical for mtDNA copy number and its dominant-negative or gain-of-function mutations is a major reason for mtDNA deletions and adPEO \[[@CR22]\]. RRM2B-mousa had a renal dysgenesis and died of sever renal dysfunction at 14th week. So p53R2 is essential for the maintenance of normal renal function \[[@CR23]\]. By contrast, there are some studies pointing out that p53R2 could promote the aggression of tumor \[[@CR8], [@CR9]\]. p53R2 enhanced the invasion of cancer through E-cadherin/β-catenin pathway \[[@CR24]\]. In esophageal squamous cell cancer, p53R2 was significantly correlated with the infiltration depth, lymph node metastasis and poor prognosis \[[@CR9]\]. p53R2 was also an adverse biomarker for the non-small cell lung cancer \[[@CR8]\]. Moreover, p53R2 was further found to be correlated with lymph node metastasis, infiltration, general stage of the tumors in oral cancer and melanoma, while there is no relationship found between p53R2 and gastric cancer \[[@CR25]--[@CR27]\].

Our result showed that p53R2 was a protective factor for the prognosis of nasopharyngeal carcinoma. These results may suggest p53R2 has the ability to repair the damaged DNA and inhibit tumor invasion. The expression of p53R2 is regulated by p53 in response to genotoxic stimulation, such as UV and chemical therapy (i.e., adriamycin) \[[@CR6], [@CR28]\], and the depletion of p53R2 can enhance the DNA damage caused by adriamycin \[[@CR29]\]. After UV treatment, p53R2 was activated and bound to hRRM1 to form RR holoenzyme to synthesize dNTP induced by UV, and then damaged DNA was impaired in the p53-mutant cell line PC3 \[[@CR29]\]. DNMT/DNA adduct formation was a prerequisite for the activation of p53R2, and the p53R2 expression was induced by nucleoside-based DNMT inhibitors which could form DNA adducts \[[@CR30]\]. It would take time to react to DNA damage after p53R2 induction, because p53R2 Ser72 phosphorylation by ataxia telangiectasia mutated (ATM) occurred within 30 min after genotoxic factors, and Ser72 phosphorylation by ATM was necessary for p53R2 stability and enduing resistance to DNA damage \[[@CR13]\]. Besides, p53R2 dominant-negative or gain-of-function mutation was a major reason for mtDNA loss and mitochondrial disease \[[@CR22]\]. Furthermore, a decreased p53R2 expression by siRNA significantly increased the cellular invasion potential in p53 mutant cell lines while the up-regulation of p53R2 could inhibit the tumor metastasis \[[@CR31]\]. The different functions of p53R2 in different cancers indicated that p53R2 had two sides in tumorigenesis. Our study reveals that the protein level p53R2 is a novel factor for NPC patients with favorable prognosis. But the mechanism under the cell function and animal experiments need further exploration.

Conclusions {#Sec15}
===========

In a conclusion, the examination of p53R2 expression, by IHC, could be used as an additional effective tool in identifying those NPC patients at favourable outcome. Our study may provide the evidence that p53R2 is a potential therapeutic target for NPC.
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